- Trials with a EudraCT protocol (1,249)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
1,249 result(s) found for: Ejection fraction.
Displaying page 1 of 63.
EudraCT Number: 2013-002091-41 | Sponsor Protocol Number: 03618 | Start Date*: 2014-10-09 |
Sponsor Name:Academisch medisch centrum | ||
Full Title: Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system | ||
Medical condition: To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003461-17 | Sponsor Protocol Number: 71272 | Start Date*: 2020-01-07 |
Sponsor Name:Amsterdam UMC, location VUmc | ||
Full Title: Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF) | ||
Medical condition: Heart failure with preserved ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001488-21 | Sponsor Protocol Number: EST:15/17 | Start Date*: 2018-11-06 |
Sponsor Name:Sergio Aleman | ||
Full Title: EFFECT OF VITAMIN D SUPPLEMENTATION ON THE VENTRICULAR DEFORMATION RATE (STRAIN RATE) IN PATIENTS WITH HEART FAILURE WITH PRESERVED OR MODERATELY REDUCED EYECTION FRACTION | ||
Medical condition: Heart failure with preserved or moderately reduced eyection fraction | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-004656-30 | Sponsor Protocol Number: ICOR-2016-05 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Instituto de Investigación en Ciencias de la Salud Germans Trias i Pujol (IGTP) | |||||||||||||
Full Title: EVOlocumab in stable Heart Failure with reduced ejection fraction of ischemic etiology: EVO-HF Pilot | |||||||||||||
Medical condition: stable coronary artery disease and stable heart failure with reduced ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002336-17 | Sponsor Protocol Number: REDUCe_2017-05-22 | Start Date*: 2017-08-06 |
Sponsor Name:Department of Clinical Sciences, Danderyd Hospital, Karolinska Intitutet | ||
Full Title: Randomized Evaluation of Decreased Usage of betablocCkErs after myocardial infarction in the SWEDEHEART registry REDUCe SWEDEHEART | ||
Medical condition: Long-term treatment with beta-blockers in patients with myocardial infarction and preserved ejection fraction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000671-25 | Sponsor Protocol Number: 1242-001 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in S... | |||||||||||||
Medical condition: Treatment of chronic heart failure with reduced ejection fraction (HFrEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) DK (Completed) NL (Completed) FI (Completed) PL (Completed) BE (Completed) GR (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003653-15 | Sponsor Protocol Number: AC-055G202 | Start Date*: 2017-09-12 | |||||||||||
Sponsor Name:ACTELION Pharmaceuticals Ltd | |||||||||||||
Full Title: A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascu... | |||||||||||||
Medical condition: Heart failure with preserved ejection fraction and pulmonary vascular disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) AT (Completed) SE (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004072-59 | Sponsor Protocol Number: 1245-0167 | Start Date*: 2018-04-03 |
Sponsor Name:Boehringer-Ingelheim España, S.A. | ||
Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa... | ||
Medical condition: Chronic Heart Failure with preserved Ejection Fraction (HFpEF) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001341-27 | Sponsor Protocol Number: Empire-2017 | Start Date*: 2017-05-29 | |||||||||||
Sponsor Name:Morten Schou | |||||||||||||
Full Title: Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF) | |||||||||||||
Medical condition: Heart failure with reduced ejection fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003055-60 | Sponsor Protocol Number: RIO-40400 | Start Date*: 2014-10-10 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, ... | ||
Medical condition: Pulmonary hypertension and heart failure with preserved ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005878-10 | Sponsor Protocol Number: ISIS757456-CS5 | Start Date*: 2021-05-06 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production, Ad... | |||||||||||||
Medical condition: Chronic Heart Failure with Reduced Ejection Fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002653-31 | Sponsor Protocol Number: VF20040171 | Start Date*: 2004-11-25 |
Sponsor Name:Odense University hospital | ||
Full Title: CAPHI. Profylactic effect of Ca2+ sensitizer versus phosphodiesterase inhibitor infusion at CAGB patients with preoperative low ejection fraction. A prospective randomised clinical trial. | ||
Medical condition: Perioperative use of Milrinon to CAGB patients has shown to reduce postoperative complications. Levosimendan improves cardiac performance without interfering with the calcium turnover and there by ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000802-46 | Sponsor Protocol Number: D169CC00001 | Start Date*: 2018-09-24 |
Sponsor Name:AstraZeneca AB | ||
Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur... | ||
Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2021-000481-14 | Sponsor Protocol Number: APHP210166 | Start Date*: 2021-12-20 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP) | ||
Full Title: Cardiometabolic effects of dapagliflozin in heart failure with reduced ejection fraction: an exploratory study. | ||
Medical condition: Heart failure with reduced ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003839-38 | Sponsor Protocol Number: BAY1067197/15128 | Start Date*: 2017-03-09 |
Sponsor Name:Bayer AG | ||
Full Title: A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral parti... | ||
Medical condition: chronic heart failure with reduced ejection fraction (LVEF equal or below 35%) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) ES (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006611-68 | Sponsor Protocol Number: shey01.2006 | Start Date*: 2007-05-07 |
Sponsor Name:academic hospital Maastricht | ||
Full Title: Valsartan on top of standard therapy as a novel therapeutic strategy to treat cardiac dysfunction in patients with infammatory cardiomyopathies | ||
Medical condition: patients suffering from heartfailure and inflammatory cardiomyopthies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002914-30 | Sponsor Protocol Number: LCZ696-17 | Start Date*: 2017-11-06 |
Sponsor Name:FIMABIS | ||
Full Title: LCZ696 in heart failure patients with reduced ejection fraction and high comorbidity: effect on left ventricular remodeling and fibrosis assessed by novel heart failure biomarkers and cardiac magne... | ||
Medical condition: Chronic heart failure NYHA class II-IV with reduced ejection fraction (EF =< 40%) and elevated NT-proBNP ≥ 600 pg/mL, but 400 pg/mL if hospitalized for heart failure within 12 months | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003604-31 | Sponsor Protocol Number: PREFER-HF | Start Date*: 2017-02-09 |
Sponsor Name:José Luis Morales Rull, Institut de Recerca Biomédica Lleida IRB Hospital Arnau de Vilanova Servicio de Medicina Interna | ||
Full Title: Effects of intravenous iron therapy with ferric carboxymaltose compared with oral iron therapy in heart failure with preserved ejection fraction and iron deficiency. ( PREFER-HF) | ||
Medical condition: Patients with heart failure with preserved ejection fraction ( HFpEF) and iron deficency anemia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005053-37 | Sponsor Protocol Number: IVOFER-HF | Start Date*: 2019-02-08 |
Sponsor Name:José Luis Morales Rull. Institut de Recerca Biomèdica de Lleida (IRBLleida) | ||
Full Title: Effect on the functional capacity of treatment with intravenous iron carboxymaltose or oral iron sucrosomial in patients with heart failure with depressed left ventricular ejection fraction and iro... | ||
Medical condition: Patients with heart failure with reduced ejection fraction ( HFrEF) and iron deficency. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-006072-32 | Sponsor Protocol Number: 2019/ABM/01/00078 | Start Date*: 2022-10-05 | |||||||||||
Sponsor Name:University Hospital in Poznań | |||||||||||||
Full Title: Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction | |||||||||||||
Medical condition: Heart Failure with reduced ejection fraction. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
